Loading clinical trials...

The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship | Clinical Trials | Clareo Health

UNKNOWNNA

The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship

NCT02806128•Huisheng Chen

View on ClinicalTrials.gov

Summary

Evaluate the effectiveness of the of kallikrein in the different drug frequency for acute anterior circulation cerebral infarction.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18 to 80 years old;
•2. First time diagnosed or have history of acute anterior circulation cerebral infarction without serious sequelae (mRS = 0-2);
•3. Acute anterior circulation cerebral infarction with large artery atherosclerotic etiology;
•4. Ability to randomize within 48 h of time last known free of new ischemic symptoms.
•5. National Institute of Health stroke scale(NIHSS) ranges from 7 to 22;
•6. signed written informed consent.

Exclusion Criteria

•1. Cerebral CT shows cerebral hemorrhage disease: cerebral hemorrhage, subarachnoid hemorrhage, etc.;
•2. Transient ischemic attack;
•3. Serious disturbance of consciousness: Glasgow Coma ScaleGCS（GCS）≤8;
•4. Combined angiotensin-converting enzyme inhibitor(ACEI) less than 5 half-time (according to its instruction), or need to be treated with ACEI;
•5. Past or present suffering from hemorrhagic tendency of the disease;
•6. The investigator in consideration of the other condition that the patients doesn't fit to participate in this clinical study.

Locations (1)

General hospital of shenyang military region

Shenyang, Liaoning, China

Key Dates

Start Date

November 1, 2016

Primary Completion Date

December 1, 2018

Last Updated

January 6, 2017

Enrollment

100

ESTIMATED participants

Conditions

Cerebral Infarction

Interventions

Human Urinary Kallidinogenase for Injection

DRUG

Contacts

Huisheng Chen

CONTACT

86-24-28897511 chszh@aliyun.com

zhonghe Zhou

CONTACT

86-24-28897511 Zhouz.h@tom.com

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

NCT06757764

Cerebral InfarctionStenosis Artery

View study

ACTIVE_NOT_RECRUITINGNA

Observation of the Therapeutic Effect of Fire Needle on Upper Limb Function in Stroke Patients

NCT07140406

Cerebral Infarction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 6, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship

Inclusion Criteria

Exclusion Criteria

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Observation of the Therapeutic Effect of Fire Needle on Upper Limb Function in Stroke Patients

Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study

The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction

The Application of Kinesio Taping Technique in the Early Upper Limb Functional Activities Induction of Hemiplegic Patients After Stroke

Effects of Armeo Power Robot Therapy on Upper Limb Recovery in Hemiplegic Stroke Patients